We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Robot Assists Endoscopic Transmyocardial Revascularization

By HospiMedica staff writers
Posted on 04 Dec 2007
A robotic surgical system that utilizes an endoscopic approach to achieve transmyocardial revascularization (TMR) can reduce patient hospitalization and recovery time.

The Port Enabled Angina Relief using Laser (PEARL) system is intended for endoscopic TMR in patients with advanced coronary artery disease. More...
The system consists of a flexible fiberoptic hand-piece that delivers precise bursts of holmium:YAG laser energy directly to an area of ischemic myocardium. The handpiece is equipped with an extended length shaft, which can be introduced via a laparoscopic approach under general anesthesia. The distal end of the shaft is flexible, and is designed to enable the grasping and manipulation of the tip by surgical robotic tools, enabling precise target area placement. Once in the proper position, the handpiece control is used to create a series of laser channels approximately one-millimeter in diameter. During a typical procedure, approximately 20 - 35 channels are made in the heart muscle; 6-10 pulses are needed to transverse the myocardium and create the channels.

The outside punctures seal over with little blood loss while the new channels allow fresh blood to perfuse the heart wall immediately, and may provide oxygen in the process. How TMR actually reduces angina is not fully understood. Researchers speculate that the laser may stimulate angiogenesis, or that it may destroy nerve fibers to the heart, making patients unable to feel their chest pain. Angina usually subsides with improved oxygen supply to the damaged areas of heart muscle. The PEARL is a product of Cardiogenesis (Irvine, CA, USA), and has been approved by the [U.S.] Food and Drug Administration (FDA).

TMR is indicated in patients whose chronic angina symptoms are not relieved by medication and who are not candidates for percutaneous coronary intervention or coronary artery bypass graft (CABG) surgery.


Related Links:
Cardiogenesis

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Patient Monitoring System
AlarmSense
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.